Capricor Therapeutics Inc. (CAPR)
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission
Capricor Therapeutics initiated its rolling BLA submission for Deramiocel to treat Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected before the end of 2024. The company presented promising 3-year data from the HOPE-2 OLE study, showing significant improvements in cardiac and skeletal muscle functions. Capricor raised $86.3 million in a public offering, ensuring sufficient cash runway to fund operations into 2027, excluding potential milestone payments from Nippon Shinyaku.
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Ted Tenthoff - Piper Sandler Leland Gershell - Oppenheimer Rick Miller - Cantor Fitzgerald Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen and welcome to the Capricor's Third Quarter 2024 Financial Results and Corporate Update Call.
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.25 per share a year ago.
Here's Why Momentum in Capricor (CAPR) Should Keep going
Capricor (CAPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?
Here is how Capricor Therapeutics (CAPR) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Capricor (CAPR) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Capricor (CAPR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Capricor (CAPR) points to a 90.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year.
Capricor Therapeutics is up over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. NASDAQ: CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year.
Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
24/7 Wall St. Insights Summer gave way to autumn this past week, and notable insider buying continued.
Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off
BLA submission of deramiocel for treatment of patients with DMD cardiomyopathy is expected in October 2024, with the completed portion expected before the end of 2024. The Duchenne Muscular Dystrophy drugs market size is projected to reach $5.5 billion by 2032. There is potential to eventually expand the label of deramiocel with positive results from Cohort A and Cohort B of the Phase 3 HOPE-3 study to target DMD skeletal muscle myopathy patients.
